<DOC>
	<DOCNO>NCT02214888</DOCNO>
	<brief_summary>Study determine efficacy ( include American College Rheumatology ( ACR ) 20 response rate ) , safety , pharmacokinetics BIRB 796 BS monotherapy patient moderate severe rheumatoid arthritis fail least one disease modify antirheumatic drug ( DMARD )</brief_summary>
	<brief_title>Efficacy , Safety Pharmacokinetics BIRB 796 BS Tablets Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Male female 18 75 year age Diagnosis rheumatoid arthritis ( RA ) establish accord ACR criterion date diagnosis &gt; 6 month Patient belong functional class I , II , III Failure least one DMARD due lack efficacy tolerability 2 3 follow RA activity criterion : If criterion meet visit 1 , whole set RA activity criterion repeat visit 2 ( Repeated screen ) documentation ≥ 9 swollen joint 66 joint count documentation ≥ 9 tender joint 68 joint count Creactive protein ( CRP ) ≥ 1.5 mg/dl erythrocyte sedimentation rate ( ESR ) ≥ 28 mm/hr ( equivalent ≥ 24mm/hr accord Panchenkov method ) Written informed consent accordance Good Clinical Practice ( GCP ) local legislation give prior study procedure , include washout prohibit medication Only centre participate pharmacokinetic ( PK ) substudy : Written inform consent accordance GCP local legislation participation PK substudy . Refusal participate PK substudy exclusion criterion participation trial Inflammatory rheumatic disease RA Treatment failure tumor necrosis factor ( TNF ) block agent . Treatment failure define achieve least ACR 20 response ( e.g . clinical trial ) clinical practice TNFblocking agent discontinue due ineffectiveness History vasculitis ( characterised e.g . nail bed hemorrhage infarct , vasculitic purpura , ulcer gangrene , multisensory neuropathy , vasculitic retinopathy scleritis eye ) . Isolated rheumatoid nodule skin criterion exclusion Serologic evidence active hepatitis B and/or C Known HIVinfection History prior tuberculosis infection suspicion active infection screen base result chest xray old 6 month History cardiovascular , renal , neurologic , psychiatric , liver , gastrointestinal , immunologic endocrine dysfunction clinically significant . A clinically significant disease define one opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study Recent history heart failure ( i.e . three year less ) myocardial infarction ( i.e . one year less ) patient cardiac arrhythmia require drug therapy History malignant disease last 5 year suspicion active malignant disease except successfully treat squamous basal cell carcinoma skin Screening ECG result outside reference range clinical relevance include , limited QTcB &gt; 480 msec , PR interval &gt; 240 msec , QRS interval &gt; 110 msec accord central ECG evaluation Clinically significant abnormal baseline hematology , blood chemistry urinalysis abnormality define disease list exclusion criterion follow specific laboratory abnormality : If criterion meet visit 1 , laboratory assessment selectively repeat visit 2 ( Repeated screen ) alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , total bilirubin great upper limit normal ( ULN ) alkaline phosphatase , creatinine white blood cell count great 1.5 x ULN History drug alcohol abuse within past two year active drug alcohol abuse , present alcohol intake three drink per day Female childbearing potential ( 6 month post menopausal surgically sterilize ) use approve form birth control ( hormonal contraceptive , oral injectable/implantable , intrauterine device ( IUD ) ) Inability comply protocol Previous enrolment trial previous exposure BIRB 796 BS another trial Hypersensitivity trial drug To assess visit 3 ( Baseline ) : Pregnancy ( exclude serum urine beta human choriongonadotropin ( βHCG ) test woman childbearing potential ) breast feed Active vasculitis Active infection serious infectious disease result hospitalisation require systemic antiinfective therapy within last 4 week DMARD treatment within last 4 week Last dose give within specified time period one follow compound drug : Infliximab ( Remicade® ) : 3 month Adalimumab ( D2E7 ) : 3 month Leflunomide : 3 month . If cholestyramine give 10 day : 4 week Investigational agent : 5 fold respective plasma half life 4 week , whichever longer Treatment systemic corticosteroid dose high 10 mg/day prednisone equivalent Change treatment nonsteroidal antiinflammatory drug ( NSAIDs ) systemic corticosteroid within last 4 week Synovectomy , joint surgery , radio/chemo synoviorthesis , adrenocorticotropic hormone ( ACTH ) steroid injection ( intraarticular , intravenous intramuscular ) within last 4 week Participation another clinical trial within last 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>